Literature review summarizes pathogenesis and treatment outcomes of CAPE, indicating benefits of biologic therapies.
CARD14-associated papulosquamous eruption (CAPE) is a rare genetically mediated inflammatory skin disorder caused by gain-of-function variants in the CARD14 gene. It typically presents in infancy or early childhood with clinical features resembling both psoriasis and pityriasis rubra pilaris, and often exhibits a poor response to conventional therapies. An increasing number of studies support favorable outcomes with biologic medications, particularly interleukin (IL)-12/23 and IL-17 inhibitors, for the treatment of CAPE. This literature review summarizes the etiology and pathophysiology of CAPE, with a focus on clinical features, genetic findings, and developments in treatment strategies.
No takes yet. Share an insight, caveat, or question.
Gavagan et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: